PDCD1 and non-small cell lung carcinoma: As these treatment-related symptoms affect patients’ quality of life, sufficient knowledge, and appropriate management of these events are important.[22,23] Our study will assess the incidence and nature of irAEs in the oncologic treatment of NSCLC using available anti-PD-1 or anti-PD-L1 antibodies through a systematic review and meta-analysis of the qualifying literature.